Single or Dual Antiplatelet Therapy in Stroke or Transient Ischemic Attack?

Antiplatelet therapy is key to prevent thrombotic events after a transient ischemic attack (TIA) or ischemic stroke. The role of aspirin is well established in this scenario, but there is emerging evidence for a short period of dual antiplatelet therapy (DAPT). Now, can this strategy avoid recurrent strokes without paying a price in terms of bleeding?

Antiagregación plaquetaria en el stroke o TIA

To answer this question, authors conducted a meta-analysis, published in STROKE, including all randomized studies comparing early start of short-term of dual antiplatelet therapy (up to 3 months) with aspirin plus a P2Y12 receptor inhibitor vs. aspirin alone in patients with stroke or transient ischemic attack.

The primary endpoint was risk of recurrent stroke, and the primary safety endpoint was major bleeding. Secondary endpoints included any stroke, hemorrhagic stroke, major cardiovascular event, and all-cause death.

Four large trials with a total of over 20,000 patients were included.

Dual antiplatelet therapy significantly lowered the risk of recurrent stroke (risk ratio [RR]: 0.76; 95% confidence interval [CI]: 0.68-0.83; p < 0.001). Its price? The rates for major bleeding doubled (RR: 2.22; 95% CI: 1.14–4.34; p = 0.02).


Read also: Watch again our Webinar “SOLACI@BIOTRONIK” on our Youtube account.


Patients receiving DAPT also had a significantly lower risk of cardiovascular events (RR: 0.76; 95% CI: 0.69–0.84; p < 0.001), and of recurrent ischemic events (RR: 0.74; 95% CI: 0.67–0.82; p < 0.001).

Conclusion

Dual antiplatelet therapy for no more than 3 months prescribed within 24 hours of a high-risk transient ischemic attack or a mild to moderate stroke significantly lowers the risk of recurrent strokes compared with aspirin alone. The cost is a significant increase in major bleeding.

We need more evidence to adequately select which patients may derive a benefit.

Título original: Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack. Meta-Analysis of Randomized Controlled Trials.

Referencia: Kirtipal Bhatia et al. Stroke. 2021 Apr 27;STROKEAHA120033033. doi: 10.1161/STROKEAHA.120.033033.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...